FDA Approves Olaparib for Frontline Maintenance in Pancreatic Cancer
The FDA has approved olaparib for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma.
Related Articles
Registration – ISLB 2024
Register for the 6th Annual Liquid Biopsy Congress, November 23-25, 2024, Denver, Colorado, USA. Shape the future of cancer diagnostics.
Registration – ISLB 2024
Register for the 6th Annual Liquid Biopsy Congress, November 23-25, 2024, Denver, Colorado, USA. Shape the future of cancer diagnostics.
Updated results from the TRANSMET trial at ESMOGI24 – OncoDaily
Updated results from the TRANSMET trial at ESMOGI24 / cancer, ESMO, ESMOGI24, OncoDaily, Oncology, TRANSMET
Accelerating the Evolution of Immune-Related Enterocolitis Management
Should biologics be the initial treatment for immune checkpoint inhibitor colitis?
The LBAs for the ESMOGI24 are now live – OncoDaily
The LBAs for the ESMOGI24 are now live / cancer, ESMO, gastrointestinal cancers, OncoDaily, Oncology
Overcoming barriers to immuno for microsatellite stable crc
Recent data indicate a role of immunotherapy for tumours with high levels of microsatellite instability, especially in the neoadjuvant setting
Perioperative Nivolumab in Resectable Lung Cancer | NEJM
Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadj…
Conference Calendar – ESMO Gastrointestinal Cancers Congress 2024
Teresa Macarulla Mercade (Barcelona, Spain) Kristen K. Ciombor (Nashville, United States of America) Pashtoon M. Kasi (New York, United States of America) Juan Manuel Ramon…
ctDNA Assays: Exploring Their Clinical Use in Oncology Care
ctDNA assays are quickly finding their way into the clinic. These assays have a potential role to play in all phases of the cancer continuum…
Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
Oncogene – Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer